: Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder

The good news on postpartum depression was offset by disappointment about major depressive disorder, which would be a far greater opportunity.

Previous post The Fed: Fed’s Williams is not in a rush to raise interest rates — or cut them
Next post Deep Dive: These 20 companies are big winners this earnings season. What do analysts think about their stocks?